CTOs on the Move

BPL Plasma

www.bplplasma.com

 
Part of UK-based Bio Products Laboratory, BPL Plasma has been a global leader in the plasma collection industry for more than 25 years. We`re proud to support the creation & manufacturing of lifesaving drug therapies by supplying high-quality plasma to people in need. At BPL Plasma, the people who walk into our centers are much more than donors — they are lifelines. Their donation, quite literally, transforms the lives of patients around the planet. Donating plasma makes it possible for: - An expectant mother to carry her child safely to term. - A little boy with hemophilia to experience a ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bplplasma.com
  • 2801 Via Fortuna Suite 400
    Austin, TX USA 78746
  • Phone: 512.582.7525

Executives

Name Title Contact Details
John Beletti
 Vice President and Chief Information Officer Profile

Similar Companies

Higher Dimension Research

Higher Dimension Research is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clene

Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland.

Cannara Biotech

Cannara plans to operate the largest indoor medical cannabis biotech facility in Quebec.

ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc is a Baudette, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zogenix

Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.